Mass Spectrometry-Based Proteomics for Pre-Eclampsia and Preterm Birth

Pregnancy-related complications such as pre-eclampsia and preterm birth now represent a notable burden of adverse health. Pre-eclampsia is a hypertensive disorder unique to pregnancy. It is an important cause of maternal death worldwide and a leading cause of fetal growth restriction and iatrogenic...

Full description

Bibliographic Details
Main Authors: Kai P. Law, Ting-Li Han, Chao Tong, Philip N. Baker
Format: Article
Language:English
Published: MDPI AG 2015-05-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:http://www.mdpi.com/1422-0067/16/5/10952
id doaj-0c8f6ba1f8204014beb275d8c64bcadb
record_format Article
spelling doaj-0c8f6ba1f8204014beb275d8c64bcadb2020-11-24T22:22:24ZengMDPI AGInternational Journal of Molecular Sciences1422-00672015-05-01165109521098510.3390/ijms160510952ijms160510952Mass Spectrometry-Based Proteomics for Pre-Eclampsia and Preterm BirthKai P. Law0Ting-Li Han1Chao Tong2Philip N. Baker3China-Canada-New Zealand Joint Laboratory of Maternal and Fetal Medicine, Chongqing Medical University, Chongqing 400016, ChinaChina-Canada-New Zealand Joint Laboratory of Maternal and Fetal Medicine, Chongqing Medical University, Chongqing 400016, ChinaChina-Canada-New Zealand Joint Laboratory of Maternal and Fetal Medicine, Chongqing Medical University, Chongqing 400016, ChinaChina-Canada-New Zealand Joint Laboratory of Maternal and Fetal Medicine, Chongqing Medical University, Chongqing 400016, ChinaPregnancy-related complications such as pre-eclampsia and preterm birth now represent a notable burden of adverse health. Pre-eclampsia is a hypertensive disorder unique to pregnancy. It is an important cause of maternal death worldwide and a leading cause of fetal growth restriction and iatrogenic prematurity. Fifteen million infants are born preterm each year globally, but more than one million of those do not survive their first month of life. Currently there are no predictive tests available for diagnosis of these pregnancy-related complications and the biological mechanisms of the diseases have not been fully elucidated. Mass spectrometry-based proteomics have all the necessary attributes to provide the needed breakthrough in understanding the pathophysiology of complex human diseases thorough the discovery of biomarkers. The mass spectrometry methodologies employed in the studies for pregnancy-related complications are evaluated in this article. Top-down proteomic and peptidomic profiling by laser mass spectrometry, liquid chromatography or capillary electrophoresis coupled to mass spectrometry, and bottom-up quantitative proteomics and targeted proteomics by liquid chromatography mass spectrometry have been applied to elucidate protein biomarkers and biological mechanism of pregnancy-related complications. The proteomes of serum, urine, amniotic fluid, cervical-vaginal fluid, placental tissue, and cytotrophoblastic cells have all been investigated. Numerous biomarkers or biomarker candidates that could distinguish complicated pregnancies from healthy controls have been proposed. Nevertheless, questions as to the clinically utility and the capacity to elucidate the pathogenesis of the pre-eclampsia and preterm birth remain to be answered.http://www.mdpi.com/1422-0067/16/5/10952pre-eclampsiapreterm birthmass spectrometryproteomicsprotein biomarkers
collection DOAJ
language English
format Article
sources DOAJ
author Kai P. Law
Ting-Li Han
Chao Tong
Philip N. Baker
spellingShingle Kai P. Law
Ting-Li Han
Chao Tong
Philip N. Baker
Mass Spectrometry-Based Proteomics for Pre-Eclampsia and Preterm Birth
International Journal of Molecular Sciences
pre-eclampsia
preterm birth
mass spectrometry
proteomics
protein biomarkers
author_facet Kai P. Law
Ting-Li Han
Chao Tong
Philip N. Baker
author_sort Kai P. Law
title Mass Spectrometry-Based Proteomics for Pre-Eclampsia and Preterm Birth
title_short Mass Spectrometry-Based Proteomics for Pre-Eclampsia and Preterm Birth
title_full Mass Spectrometry-Based Proteomics for Pre-Eclampsia and Preterm Birth
title_fullStr Mass Spectrometry-Based Proteomics for Pre-Eclampsia and Preterm Birth
title_full_unstemmed Mass Spectrometry-Based Proteomics for Pre-Eclampsia and Preterm Birth
title_sort mass spectrometry-based proteomics for pre-eclampsia and preterm birth
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1422-0067
publishDate 2015-05-01
description Pregnancy-related complications such as pre-eclampsia and preterm birth now represent a notable burden of adverse health. Pre-eclampsia is a hypertensive disorder unique to pregnancy. It is an important cause of maternal death worldwide and a leading cause of fetal growth restriction and iatrogenic prematurity. Fifteen million infants are born preterm each year globally, but more than one million of those do not survive their first month of life. Currently there are no predictive tests available for diagnosis of these pregnancy-related complications and the biological mechanisms of the diseases have not been fully elucidated. Mass spectrometry-based proteomics have all the necessary attributes to provide the needed breakthrough in understanding the pathophysiology of complex human diseases thorough the discovery of biomarkers. The mass spectrometry methodologies employed in the studies for pregnancy-related complications are evaluated in this article. Top-down proteomic and peptidomic profiling by laser mass spectrometry, liquid chromatography or capillary electrophoresis coupled to mass spectrometry, and bottom-up quantitative proteomics and targeted proteomics by liquid chromatography mass spectrometry have been applied to elucidate protein biomarkers and biological mechanism of pregnancy-related complications. The proteomes of serum, urine, amniotic fluid, cervical-vaginal fluid, placental tissue, and cytotrophoblastic cells have all been investigated. Numerous biomarkers or biomarker candidates that could distinguish complicated pregnancies from healthy controls have been proposed. Nevertheless, questions as to the clinically utility and the capacity to elucidate the pathogenesis of the pre-eclampsia and preterm birth remain to be answered.
topic pre-eclampsia
preterm birth
mass spectrometry
proteomics
protein biomarkers
url http://www.mdpi.com/1422-0067/16/5/10952
work_keys_str_mv AT kaiplaw massspectrometrybasedproteomicsforpreeclampsiaandpretermbirth
AT tinglihan massspectrometrybasedproteomicsforpreeclampsiaandpretermbirth
AT chaotong massspectrometrybasedproteomicsforpreeclampsiaandpretermbirth
AT philipnbaker massspectrometrybasedproteomicsforpreeclampsiaandpretermbirth
_version_ 1725768554456809472